Rubicon Genomics was founded in 2000 by two University of Michigan faculty members who wanted to advance the translation of human genetics laboratory knowledge into practical medicine applications. The founders also decided to maintain the company's roots in Michigan with a commitment to supporting the Michigan economy. Today, Rubicon Genomics is a privately held company located in Ann Arbor, Michigan. Our innovative products combined with our strategic partnerships have established the company as a leader in pre-analytical amplification technologies that "break the sample barriers" for our customers. Rubicon sells its products into the research and commercial markets directly and through distributors. Rubicon Genomics intends to be the premiere provider of technology for the pre-analytical amplification of nucleic acid for research and commercial applications. Rubicon is taking advantage of its technologies: simple protocols, fast time to results and unique ability to amplify nucleic acid from difficult samples to develop differentiated products that enable researchers and healthcare providers to more easily and cost-effictively realize the benefits of the genomic revolution. Rubicon Genomics' core competencies include enzymology, nucleic acid chemistry, sample processing and manufacturing.